Skip to content
HowShorted

Anika Therapeutics Inc. short interest in 2025

In 2025, Anika Therapeutics Inc.'s disclosed short interest ran from 2.75% of shares outstanding on 15 Jan 2025 to 4.04% on 31 Dec 2025, a change of +1.29 percentage points. The year's high was 4.04% on 31 Dec 2025 and its low 2.14% on 15 Oct 2025, averaging 2.74% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.70 days on 13 Jun 2025. Full history: Anika Therapeutics Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Anika Therapeutics Inc. in 2025

2025 in figures

Start of year
2.75% (15 Jan 2025)
End of year
4.04% (31 Dec 2025)
Change
+1.29 pp
High
4.04% (31 Dec 2025)
Low
2.14% (15 Oct 2025)
Average
2.74%
Highest days to cover
8.70 (13 Jun 2025)
SEC filings marked
8

Every report in 2025

Anika Therapeutics Inc. short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 20252.75%5.80
31 Jan 20252.63%7.00
14 Feb 20252.60%6.01
28 Feb 20252.55%6.38
14 Mar 20252.76%3.80results (8-K)
31 Mar 20252.75%5.0810-K filed
15 Apr 20252.74%5.15
30 Apr 20252.83%8.21
15 May 20252.87%4.8210-Q filed, results (8-K)
30 May 20252.91%6.07
13 Jun 20253.06%8.70
30 Jun 20252.96%5.19
15 Jul 20252.28%2.04
31 Jul 20252.52%2.3710-Q filed, results (8-K)
15 Aug 20252.77%3.05
29 Aug 20252.80%3.30
15 Sep 20252.50%4.65
30 Sep 20252.34%2.77
15 Oct 20252.14%3.44
31 Oct 20252.15%3.24
14 Nov 20252.30%2.1010-Q filed, results (8-K)
28 Nov 20253.07%2.45
15 Dec 20253.48%2.99
31 Dec 20254.04%3.58

See also: Anika Therapeutics Inc.'s full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.